http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2749117-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b69b8af6db128c4f2f161aa170e37a9d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-571 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-571 |
| filingDate | 2020-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3be5feac550006c4d9f27154b1cfd8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_300f7e784107d93072118511d5359797 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aceda5219d16445759eb9fb579878636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da5ec1a77727f7babcc6595cfbc5ffad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d9c37a999046183a450992f10db80a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08dd6cf5b182ddc61966bd1a7caf52be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01d4686c2b7aa05cc7c32ce548e7d3da |
| publicationDate | 2021-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2749117-C1 |
| titleOfInvention | Method for prediction of risk of development of hepatocellular carcinoma in patients with chronic hepatitis c |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to medicine and relates to a method for predicting the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C. The essence of the method lies in the fact that a set of indicators of the level of alpha-fetoprotein, glypican-3 and ostepontin in venous blood is determined. The threshold value is pre-calculated for each tumor marker. The result is compared with the threshold values for alpha-fetoprotein (16.0 ng / ml); for osteopontin (80.0 ng / ml); for glypican-3 (1.0 ng / ml). The risk of developing the disease is predicted according to the following algorithm: if the level of three detectable tumor markers is less than or equal to the threshold value, there is no risk of developing hepatocellular carcinoma; if the threshold value of one of the tumor markers is exceeded, the risk of developing the disease is low; when the threshold value of two tumor markers is exceeded, the risk of developing the disease is high; when the threshold value of three detectable tumor markers is exceeded, the absolute risk of developing hepatocellular carcinoma is predicted.EFFECT: use of the method allows predicting with high accuracy the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C.1 cl, 1 dwg, 3 ex, 3 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2800251-C1 |
| priorityDate | 2020-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 78.